Editor's Note: Female sexual dysfunction (FSD) as a discipline of medicine is not fully recognized by many authorities. Definitions are controversial and data are lacking, yet the public clamors for treatment. The lay press has capitalized on this provocative women's issue, seizing on the public's insatiable desire for new, potentially 'sexy' therapeutic options in this area. Thus, the time was ripe for a potential FSD drug. The sexual medicine community watched with interest as the Food and Drug Administration (FDA) considered the Proctor & Gamble new drug application for Intrinsa (a testosterone patch for hypoactive sexual desire disorder for women who had undergone surgical castration via bilateral oophorectomy). In spite of quality scientific data, Intrinsa was not approved. With this issue of IJIR, a new column, entitled, 'perspective' is provided to the readership. Perspective is an invited opinion or viewpoint that aims to advise and update the medical community on a pertinent or current topic in sexual medicine. Dr Richard Spark, a noted endocrinologist, presents the first of three invited 'perspectives' on Intrinsa and the FDA decision. Dr Spark has authored several manuscripts on the topic of FSD. The FDA advisory panel's failure to recommend approval for Intrinsa, the 300 mg testosterone patch intended to treat hypoactive sexual disorder (HSDD) in women, was surely a disappointment for Proctor & Gamble (P&G) and Watson pharmaceuticals, the marketer and developer of the patch, respectively, as well as a shock to a salivating media already proclaiming Intrinsa to be a 'female Viagra'.
The FDA advisory panel's failure to recommend approval for Intrinsa, the 300 mg testosterone patch intended to treat hypoactive sexual disorder (HSDD) in women, was surely a disappointment for Proctor & Gamble (P&G) and Watson pharmaceuticals, the marketer and developer of the patch, respectively, as well as a shock to a salivating media already proclaiming Intrinsa to be a 'female Viagra '. Here is what was presented to the FDA Postmenopausal women studied had bilateral oophorectomy, HSDD, lowered testosterone levels and were assigned to treatment with either a placebo or the testosterone-impregnated Intrinsa patch. All received estrogen supplements. The data showed a clear albeit modest improvement in sexual satisfaction in the women treated with the Intrinsa patch. Testosterone-treated women reported a 54% improvement in sexual function compared to 31% improvement reported in placebo-treated women. The panel voted 14-3 that this was an effective treatment. The side effects of acne and hirsutism were somewhat more common in the Intrinsatreated women, but not enough to bother the FDA panel. Changes in lipid levels and other laboratory safety tests did not raise any alarms.
So why wasn't Intrinsa approved?
The Women's Health Initiative (WHI) experience apparently weighed heavily on the panel members who were unwilling to approve any medication, particularly a 'sex steroid', until they could be sure the medication did not increase the risk of breast cancer, heart attack or stroke. Recall that the initial WHI study found that menopausal women taking a conjugated estrogen-progesterone combination pill for 5 y had an increase in breast cancer rate of 0.8% per year and more heart attacks than comparably aged placebo-treated women.
The panel was apparently concerned that adding another sex steroid-even though the steroid was testosterone and not progesterone-'might have similar and unanticipated adverse effects'. More safety data were required. That was the official reason for not recommending Intrinsa's approval, but there is also a subtext that deserves some attention.
Beyond safety concerns, other issues such as an unwillingness to recognize HSDD as an important disorder warranting clinical concern (remember the furor after sildenafil was approved to treat a non life threatening condition such as ED), a dismissal of the modest benefits afforded by 'one more satisfying sexual event per four weeks' as well as a problem coping with the whole issue of female androgen insufficiency.
Defining androgen deficiency in females
Ever since the Princeton conference validated the concept of a female androgen deficiency syndrome, doctors have been scrambling to decide just how much androgen a women needs. We know that the ovaries start secreting testosterone when a young woman starts menstruating and when estrogen secretion ceases at menopause so does ovarian testosterone secretion. The menopausal decline in estrogen production is accompanied by a reflex increase in pituitary follicle-stimulating hormone (FSH) levels, providing hormonal confirmation that the hot flashes a menopausal woman is experiencing are indeed a reflection of her estrogen deficiency. (A less impressive luteinizing hormone (LH) increase accompanying the testosterone decline hardly raises eyebrows.)
Although circulating estradiol levels plummet at menopause, testosterone does not vanish from a woman's blood stream. Schifren demonstrated that even in oophorectomized women, testosterone persists in a woman's circulation at lower levels than in young menstruating women. (This is likely due to peripheral conversion of adrenal androgen precursors into testosterone.) In oophorectomized women, a 150 mg testosterone patch raises serum testosterone levels to the young female range, but does not improve sexual function. Only by using the higher dose (300 mg) testosterone patch and increasing testosterone to supraphysiologic levels above those that sustain sexual function in younger women do oophorectomized women report an improvement in their sexual function.
In this regard, female testosterone deficiency differs from all other hormone-deficient states. In men and women with adrenal insufficiency, hypothyroidism and subnormal testosterone clinical improvement is apparent when physiologic hormone levels are achieved. Thus, for all conditions (except female androgen insufficiency) effective hormone replacement is similar to the porridge preference 'not too hot, not too cold, but just right' principle exemplified by the Goldilocks and the Three Bears fairy tale.
Why women with HSDD require testosterone levels greater than they had when they were young to experience an improvement in sexual function has not yet been explained.
Where to from here?
It is unlikely that P&G will have the resources to conduct a 17 000 patient WHI trial independently. P&G will have safety data on women, from the original trials, who continue on this medication and will soon have safety data on 200 women who have used the patch for a year. They can add to that another 100 women who will have completed 18 months of Intrinsa and another 80 women who have used Intrinsa for 3 y. Whether the safety data from these 380 patients will suffice remains to be determined.
For women with HSDD disappointed by the FDA's decision and still eager to bolster their own androgen levels, the estradiol testosterone combination pill (Estratest) remains on the market, although the warning of an increase in endometrial cancer from the estrogen component may alarm some women.
Dehydroepiandrosterone tablets are readily available as an over the counter androgen and can be converted into other androgens and eventually increase circulating testosterone levels in women.
Conclusion
The P&G experience will likely cast a pall on others currently developing androgen-based products to treat female HSDD. While it is understandable that in a search for a billion dollar medication, P&G would condone the Intirnsa/Viagra comparison, this should be discouraged for Viagra does not increase sexual desire in men and is proved to be ineffective for women even with the narrowly construed 'female arousal disorder' indication.
Author disclosure: Dr Spark has conducted research for Pfizer, is on the Pfizer board of consultants and a scientific advisor for Lilly.
